XOMA begins US clinical trial of gevokizumab to treat Behcet's disease uveitis

US-based therapeutic antibodies manufacturer XOMA has started patient enrolment in its EYEGUARD-US supplemental clinical trial designed to evaluate the efficacy and safety of gevokizumab in treating Behçet's disease uveitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news